Explore the latest news and updates from Pairidex® as we progress along the path to delivering smarter, faster, and more compassionate blood cancer care.
ST. LOUIS, MO, UNITED STATES, February 23, 2026 /EINPresswire.com/ -- Pairidex, an emerging leader in leukemia detection, today announced a lead investment from BioGenerator Ventures that will enable the launch of FusionMRD™, a new personalized, RNA-based assay for the monitoring of measurable residual disease (MRD) in fusion-driven hematological malignancies. FusionMRD™ is commercially available as a laboratory developed test (LDT) for...
PAIRIDEX Headquarters: St. Louis (BioGenerator Labs in the Cortex district) What it does: Pairidex is developing a novel droplet digital PCR platform for more accurate, personalized monitoring of blood cancer. The latest: Pairidex established operations just over one year ago. Since then, Pairidex has closed an oversubscribed pre-seed round, licensed the necessary IP from WashU, established a CLIA-certified laboratory, and completed its first commercial sale. Why you should watch it: Our mission is to...
From Small-Town Roots to Bioscience Innovation When all the pieces fall into place, miraculous things happen. Hannah Davis is living proof. At 23, she’s a promising scientist and Research Associate at Pairidex, Inc., a company focused on pioneering blood cancer detection methods—potentially life-saving innovations for leukemia patients. Her journey, from a small-town high school to cutting-edge biomedical research, represents the full realization of BioSTL’s vision to change the world...